Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fixed-dose versus weight-adjusted ivermectin for uncomplicated strongyloidiasis
2022-004143-27Phase 2Active
- Sponsor
- Vall d'Hebron Research Institute
- Start
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of ivermectin in strongyloidiasis (2 arms), sponsored by Vall d'Hebron Research Institute. Primary endpoint: Proportion of patients with microbiological cure at 6 months of treatment. Started Feb 2023; status: active.
02
Drugs
ivermectin
03
Conditions
strongyloidiasis
Beyond the preview
Go deeper on 2022-004143-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-004143-27.